In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nabriva Therapeutics PLC

www.nabriva.com

Latest From Nabriva Therapeutics PLC

New Tech Payment For Old Antibiotics: US Medicare Effort Brings Lots Of Interest

CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.

Infectious Diseases Reimbursement

Promising Shionogi Candidate Moves Ahead In Gram-Negative Pneumonia

Novel Shionogi antibiotic candidate set to move ahead following positive results in Gram-negative pneumonia, where resistance and unmet needs remain critical factors.
Infectious Diseases Clinical Trials

Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen

The latest drug development news and highlights from our US FDA Performance Tracker.
Approvals Drug Review

Nabriva Faces Skepticism After Years Of Preparing For Novel Antibiotic Xenleta's Launch

Lefamulin was approved in the US to treat community-acquired bacterial pneumonia, providing a needed IV and oral drug initially in the hospital setting, but new antibiotics have been a tough sell.

Infectious Diseases Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Antibiotic Research Institute
  • Nabriva Therapeutics AG
  • 1641640
  • Nabriva Therapeutics Forschungs GMBH
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Nabriva Therapeutics PLC
  • Senior Management
  • Ted Schroeder, CEO
    Gary Sender, CFO
    Francesco Maria Lavino, Chief Commercial Officer
    Jennifer Schranz, MD, CMO
    Steven Gelone, MD, CSO & Head, Bus. Dev.
  • Contact Info
  • Nabriva Therapeutics PLC
    Phone: (43) 1 649 2000
    25-28 North Wall Quay
    Dublin, 1
    Ireland
UsernamePublicRestriction

Register